Sulfasalazine Monitoring Information

Dr H L Averns

This shared care guideline sets out details for the sharing of care of patients with rheumatoid arthritis prescribed sulfasalazine. These guidelines provide additional limited information necessary to aid in the treatment of rheumatology patients. As with all shared care guidelines these highlight significant prescribing issues but should be used in conjunction with the summary of product characteristics (Data sheet) and do not replace the drug company information.

INDICATIONS FOR THE PURPOSES OF THIS GUIDELINE

Management of adults with inflammatory joint disease.

Sulfasalazine usually takes 3-4 months to show an effect.

DOSE

Week 1  –  500mg each evening
Week 2  –  500mg twice daily
Week 3  –  500mg in the morning and 1 gram evening
Week 4  –  1 gram twice daily

The dose may be increased to 3 grams if no response (after 3 months).

Tablets should not be crushed or broken. It is recommended that the tablets should be taken with water.

CONTRAINDICATIONS

- Children under 2 years of age (N.B. Use in children over 2 years of age is outside the scope of this guideline)
- Patients with significant hypersensitivity to sulphonamides or salicylates
- Patients with a history of acute intermittent porphyria

PRECAUTIONS

- Hepatic disease
- Glucose-6-Phosphate dehydrogenase deficiency
- Diabetes, there is the possibility of interference with blood glucose regulation
• Previous significant hepatic drug reactions may mean increase of side effects due to sulfapyridine metabolite.
• Pregnancy - Sulfasalazine has been given safely during pregnancy. However, all drugs can potentially affect the unborn child. Men and women of childbearing potential are advised therefore to use a reliable method of contraception during and for three months after treatment. When planning a pregnancy it is important that both men and women on this drug discuss medication with the Rheumatology Team. This should be at least six months before conception.
• Breastfeeding is acceptable with the small amounts of sulfasalazine that are secreted.

MONITORING
PRIOR TO STARTING THERAPY:

Measure baseline FBC, LFTs and renal function

ONGOING MONITORING:

• FBC and LFT’s fortnightly for the first three months then 3 monthly thereafter.
• In order to monitor disease activity 3 monthly CRP would be helpful.

STOP AND REFER TO THE RHEUMATOLOGY TEAM IF:

• Rash.
• Liver enzymes especially transaminase increased x 3 upper limit of normal.
• WCC falls on 3 successive occasions and/or WCC falls below 3.5 x 10^9
• Platelet count falls on 3 successive occasions
• Platelet count falls below 150 x 10^9

SIDE EFFECTS

75% of all side effects are seen within 3 months of starting sulfasalazine and 90% are identified within 6 months.

Patients must report mouth ulcers, sore throat, fever, epistaxis, purpura, unexpected bruising or bleeding, and any unexplained illness/infection and should be seen urgently for full blood count and liver function tests.

Very common/Common:

• Discolouration of urine and other secretions
• Certain types of extended wear contact lenses may be permanently stained during therapy
• Nausea, vomiting, rash, headache, raised temperature and loss of appetite in approximately 15% (try reducing dose).
• Diarrhoea, abdominal pain, exacerbation of symptoms of colitis, headache, hypersensitivity reactions (including rash and urticaria)

Uncommon:

• Bone marrow suppression and hepatitis are rare but monitoring mandatory at onset of treatment.
• Oligospermia (reversible).
• Rarely:
  • Acute pancreatitis
  • Lung disorders
  • Vertigo, tinnitus, peripheral neuropathy, aseptic meningitis, ataxia, convulsions, insomnia, mental depression and hallucinations
  • Renal dysfunction
  • Skin reactions (including lupus erythematosus-like syndrome, Stevens-Johnson syndrome), photosensitization, and alopecia.

COMMON/SIGNIFICANT DRUG INTERACTIONS

• Absorption of digoxin and folate may be reduced
• Ampicillin and Rifamipicin may alter sulfasalazine levels
• Toxicity increased when Azathioprine or Mercaptopurine are co-prescribed.
• Warfarin levels may be affected on starting Sulfasalazine
• Antacids may decrease the absorption of sulfasalazine

REFERENCES
Summary of Product Characteristics: Salazopyrin-EN January 2006
http://emc.medicines.org.uk/
http://www.rheumatology.org.uk
BNF 50
Stockley’s Drug Interactions 7th Ed

Date of Issue Nov 2006
Review Date sept 2013